Immunotherapy and chemo before and after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or III non-small cell lung cancer (NSCLC) that can be surgically removed.
- You have not had any previous cancer treatment for your lung cancer (like chemotherapy, radiation, or surgery).
- Your tumor does not have an EGFR or ALK gene mutation.
- You are in good general health (able to do daily activities without help) and your organs work well enough for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.